Gilead ramps up production of experimental Covid-19 treatment amid criticism over access
ERIC RISBERG/AP
“Providing our existing supplies at no charge is the right thing to do,” wrote Gilead chief executive officer Daniel O’Day in an open letter.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario